Naik, Rakhi - Johns Hopkins University

个人简介

Dr. Rakhi Naik is the Associate Program Director for Hematology for the Hematology/Oncology Fellowship and is an Assistant Professor of Medicine at Johns Hopkins. She received her undergraduate degree in Biomedical & Electrical Engineering from Duke University and her M.D. with Honors in Research from Cornell University. She then completed her Internal Medicine Residency and Hematology Fellowship training at Johns Hopkins, where she also served as Assistant Chief of Service (Chief Resident). Dr. Naik has additionally received a Masters in Health Science (MHS) from the Graduate Training Program in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health. Dr. Naik specializes in the treatment of adult patients with blood and bone marrow disorders. Her primary focus is caring for patients with coagulation disorders such as abnormal bleeding and clotting, immune cytopenias such as ITP, AIHA, and TTP, myeloid disorders, and hemoglobinopathies.

研究领域

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Dr. Naik’s research focuses on the epidemiology of clinical complications of sickle cell trait, including chronic kidney disease and venous thromboembolism. Currently, very little is known about the clinical consequences of sickle cell trait. The goal of Dr. Naik's research is define the risk and modifying factors for disease related to sickle cell trait in order to inform genetic counseling, screening and treatment recommendations in individuals with trait. Another main focus of Dr. Naik's research is the epidemiology and unique mechanisms of thrombosis in patients with hemoglobin disorders. Hypercoagulability in patients with hereditary hemoglobin disorders such as sickle cell disease results in severe complications such as venous thromboembolism and stroke. The primary aim of Dr. Naik’s research in this area is to characterize this thrombotic risk with the goal of identifying novel mechanisms of hypercoagulability and developing effective therapeutic strategies in patients with hemoglobinopathies.